New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Burcu Isler, Yohei Doi, Robert A. Bonomo, David L. Paterson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

Original languageEnglish
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number1
DOIs
Publication statusPublished - 01-2019
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this